DK0958500T3 - Immunohistokemisk påvisningsassay for carcinomproliferationsstatus - Google Patents

Immunohistokemisk påvisningsassay for carcinomproliferationsstatus

Info

Publication number
DK0958500T3
DK0958500T3 DK97952197T DK97952197T DK0958500T3 DK 0958500 T3 DK0958500 T3 DK 0958500T3 DK 97952197 T DK97952197 T DK 97952197T DK 97952197 T DK97952197 T DK 97952197T DK 0958500 T3 DK0958500 T3 DK 0958500T3
Authority
DK
Denmark
Prior art keywords
detection assay
immunohistochemical detection
sample
carcinoma
proliferation status
Prior art date
Application number
DK97952197T
Other languages
English (en)
Inventor
Michael N Gould
Steven P Stoesz
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of DK0958500T3 publication Critical patent/DK0958500T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97952197T 1997-01-06 1997-11-18 Immunohistokemisk påvisningsassay for carcinomproliferationsstatus DK0958500T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/779,870 US5846739A (en) 1995-12-05 1997-01-06 Immunohistochemical detection assay for carcinoma proliferative status
PCT/US1997/020998 WO1998030907A1 (en) 1997-01-06 1997-11-18 Immunohistochemical detection assay for carcinoma proliferative status

Publications (1)

Publication Number Publication Date
DK0958500T3 true DK0958500T3 (da) 2002-10-07

Family

ID=25117836

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97952197T DK0958500T3 (da) 1997-01-06 1997-11-18 Immunohistokemisk påvisningsassay for carcinomproliferationsstatus

Country Status (12)

Country Link
US (1) US5846739A (da)
EP (1) EP0958500B1 (da)
JP (1) JP3336016B2 (da)
AT (1) ATE222366T1 (da)
AU (1) AU712949B2 (da)
CA (1) CA2271092C (da)
DE (1) DE69714778T2 (da)
DK (1) DK0958500T3 (da)
ES (1) ES2182140T3 (da)
IL (1) IL129766A (da)
NZ (1) NZ335535A (da)
WO (1) WO1998030907A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517513B1 (en) * 1999-01-21 2003-02-11 Neomatrix, Llc Intraductal breast fluid aspiration device
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2001077682A1 (fr) * 2000-04-10 2001-10-18 Institut Bioorganicheskoi Khimii Imeni Akademikov M.M. Shemyakina I Ju. A. Ovchinnikova Rossiisskoi Akademii Nauk Anticorps diriges contre le facteur hldf, procedes de fabrication correspondants, peptides avec des capacites antigeniques et a hydrolyse hk et procede de diagnostic de l'etat anaplasique de cellules humaines
RU2276672C2 (ru) * 2000-04-10 2006-05-20 Институт Биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова Российской Академии Наук Антитело к фактору hldf, способ его получения (варианты), пептид с антигенными и нк-гидролизующими свойствами и способ диагностики анапластического состояния клетки человека
US6866994B2 (en) 2001-05-30 2005-03-15 Neomatrix, Llc Noninvasive intraductal fluid diagnostic screen
DE10230631A1 (de) * 2002-07-02 2004-01-22 Metagen Pharmaceuticals Gmbh Verwendungen von an Ngal bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
WO2006105141A1 (en) 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
CA2742291A1 (en) * 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, andmethods of enrichment, analysis and use
US9187567B2 (en) 2011-05-18 2015-11-17 Parkinson's Institute Assay to determine LRRK2 activity in parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024065A1 (en) * 1995-02-03 1996-08-08 Oncogene Science, Inc. Methods for the detection of pro-cathepsins and uses thereof
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level

Also Published As

Publication number Publication date
DE69714778D1 (de) 2002-09-19
IL129766A (en) 2002-02-10
US5846739A (en) 1998-12-08
JP3336016B2 (ja) 2002-10-21
AU5586798A (en) 1998-08-03
CA2271092A1 (en) 1998-07-16
IL129766A0 (en) 2000-02-29
ES2182140T3 (es) 2003-03-01
ATE222366T1 (de) 2002-08-15
EP0958500A1 (en) 1999-11-24
DE69714778T2 (de) 2003-04-10
CA2271092C (en) 2004-02-10
EP0958500B1 (en) 2002-08-14
NZ335535A (en) 2000-08-25
WO1998030907A1 (en) 1998-07-16
AU712949B2 (en) 1999-11-18
JP2000508074A (ja) 2000-06-27

Similar Documents

Publication Publication Date Title
ATE406834T1 (de) System zur überwachung der konzentration von analyten in körperflüssigkeiten
NO20010011L (no) Optisk sensor for in-situ-måling av analytter
BR9911291A (pt) Diagnóstico diferencial de neurodegeneração
DE69929185D1 (de) Tumormarker
IL172997A0 (en) Device and method for simultaneous carrying out of blood group determination, serum cross-check and antibody detection test
ATE449865T1 (de) Teststreifen zum analytnachweis und verwendungsverfahren
ATE267399T1 (de) Verfahren zum nachweis von komplex-gebundenem prostata-spezifischem antigen (kpsa)
DE69910003D1 (de) Überwachung physiologischer analyte
DE69330067D1 (de) Analytische testvorrichtung einschliesslich negativ- und positivkontrolle
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
DE69714778D1 (de) Immunohistochemischer nachweis des proliferativen zustandes von karzinoma
DE69607176D1 (de) Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper
DE69941627D1 (de) Für krebs
DE68925058D1 (de) Verfahren zum frühzeitigen Nachweis von Lungenkrebs
EP1563308A4 (en) METHOD AND KITS FOR TUMORIGENICITY DIAGNOSIS
DE50104561D1 (de) Verfahren zur Diagnose von Sepsis unter Bestimmung löslicher Cytokeratinfragmente
ZA202300353B (en) Lateral flow assay device for detection of analytes and method of detection thereof
DE69636749D1 (de) Methode zur bestimmung von proteinfragmenten in körperflüssigkeiten
DE69736336D1 (de) Verfahren zur messung von blutersatzstoffen
US20050064506A1 (en) Method for diagnosis of sepsis by determination of S100B
DE50103032D1 (de) Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 19-9
WO2002057793A3 (en) Method of detecting prp protein and kits therefor
DE50101715D1 (de) Verfahren zum nachweis von alpha-oxoaldehyden in vollblut, blutplasma und/oder serum eines patienten
WO1998046993A3 (en) Method for diagnosing cancer by measuring the presence of creatine kinase inhibitor
ZA202207380B (en) Quantification of polynucleotide analytes from dried samples